IDX enhances the anti-tumor effect of cisplatin in aggressive
NPC cancer phenotypes in vitro
(A) Four NPC cell lines (NPC43 EBV-positive, NPC43+ve in blue;
NPC43EBV-negative, NPC43-ve in red; C666 in black; C17 in green) were
treated with increasing concentrations of IDX and cisplatin (cis)
ranging from 1 µM to 40 µM. The viability of cells treated with IDX for
5 days was analyzed by XTT cell proliferation assay. (B) Representative
images of cell migration in 8 µm transwell upon IDX treatment, stained
with crystal violet, with the migratory cell counts shown next to the
images. (C) Representative flow cytometric profiles showing Annexin V
and PI staining of NPC cells following IDX treatment. (D) Bar graph
represent the percentage of Annexin-V/PI positive NPC cells following
IDX treatment. Asterisk to the right of bar indicate statistical
difference compare to control DMSO in respective cell lines. (E)
Viability of cells treated with cisplatin (Cis) for 5 days was analyzed
by XTT assay. (F) Combinatorial treatment of IDX at 1, 2, 4 µM and Cis
at 0.6, 1.2, 2.6 µM in four NPC cell lines by XTT assay. (G)
Representative images of cell growth following IDX and/or cis treatment,
stained with crystal violet. (H) Quantification of cell growth is shown.
Results are representative of three independent experiments and
presented as the means ±SD *p<0.05, **p<0.01.